®Presbyopia turns an ordinary moment—reading a message, checking a price, following instructions—into a daily negotiation with near vision. For a company developing personalized vision care, that recurring need creates a compelling starting point. Yolia’s commercial opportunity sits at the intersection of population aging, an established contact lens industry, and growing interest in convenient, individualized treatment.
TVT, Yolia’s True Vision Treatment platform, combines customized gas-permeable contact lenses with proprietary ophthalmic formulations in a nonsurgical corneal modulation approach. Its business case is strongest when built around a defined patient experience, a reproducible clinical service and a practical route to delivery. Large demographic numbers establish the relevance of the problem; a focused commercialization model translates that relevance into a business.
A global need with a long demographic runway
A systematic review and modeling study published in Ophthalmology estimated that 1.8 billion people had presbyopia in 2015. Within that population, approximately 826 million had near vision impairment because correction was absent or inadequate. These are historical modeled estimates, with the second group forming a subset of the first. They describe the scale of need rather than the number of people eligible for, or able to purchase, TVT. [1]
The demographic direction remains favorable for presbyopia-focused innovation. The World Health Organization projects that one in six people worldwide will be aged 60 or older by 2030. That trend supports the strategic importance of near vision care, while clinical eligibility and purchasing behavior still require their own assessment. [2]
For Yolia, the opportunity begins with people who value functional near vision and seek a personalized nonsurgical option. The first commercial market should be defined by specific clinical criteria, local authorization, patient access and provider capability. Expansion can then follow evidence and operating experience.
Contact lenses demonstrate an established commercial ecosystem
Contact lenses bring an important advantage to this opportunity: patients, practitioners, manufacturers and distributors already participate in a substantial global industry.
In its January–February 2026 annual report, Contact Lens Spectrum, drawing on a contribution from Baird analyst Jeff Johnson, described a roughly $12 billion global contact lens market. Its assessment based on the first nine months of 2025 indicated approximately 4% growth for that year. This is an attributed industry estimate, rather than an audited market total or a measure of TVT’s addressable revenue. [3]
Company disclosures provide additional evidence of the category’s commercial scale:
| Indicator | Reported period | What it measures |
|---|---|---|
| Alcon contact lens sales: $2.770 billion | Year ended December 31, 2025 | One company’s contact lens revenue; growth of 6% reported and 5% in constant currency |
| CooperVision sales: $2.744 billion | Fiscal year ended October 31, 2025 | One company’s vision-care segment revenue |
| CooperVision toric and multifocal sales: $1.351 billion | Same fiscal year | A subset of CooperVision sales; growth of 7% reported |
Sources: Alcon and CooperCompanies. [4,5] These figures illustrate existing business activity. They should not be added to the global market estimate, and the toric/multifocal category includes more than presbyopia or individually customized products.
For Yolia, this ecosystem may support future partnerships in lens design, manufacturing, fitting and professional distribution. The strategic task is to establish how TVT can fit into clinical workflows and create value for patients and providers.
Convenience and specialized optics are shaping expectations
Patients increasingly evaluate vision care through the experience of using it: comfort, simplicity, daily routines and the ability to see at the distances that matter to them.
NIQ reported in April 2026 that daily disposable contact lenses represented 61% of the value in its global tracking, compared with 57% in 2022. This provides a directional signal of demand for convenience within the tracked contact lens category. It does not establish willingness to pay for TVT or prove that one treatment approach is preferred over another. [6]
Specialized optical products also have a meaningful commercial presence, as CooperVision’s combined toric and multifocal results show. For Yolia, personalization can be expressed in a concrete service proposition: measurements that guide treatment, a lens fitted to the individual, and follow-up that documents the patient’s experience and clinical response.
The commercial value of that proposition should be measured through eligibility, treatment completion, functional outcomes, satisfaction and provider economics. Those measures connect a differentiated technology to a scalable care model.
Turning market scale into a business plan
A persuasive business plan moves from worldwide need to a defined launch population. For TVT, the practical sequence is:
People with relevant vision needs → clinically eligible patients → authorized and accessible markets → patients willing and able to pay → treatment capacity at participating sites.
This approach gives investors and partners a clear basis for evaluating growth. An initial revenue model can use:
Active treatment sites × new patients per site per month × operating months × net company revenue per treatment course.
Each assumption can be tied to a pilot, contract or observed operating result. Net company revenue should be separated from the full patient bill. Any repeat-treatment revenue should reflect supported treatment intervals and observed retention rather than an assumed subscription.
This framework also highlights practical opportunities for value creation: efficient patient selection, consistent fitting, reliable formulation supply, practitioner training and accessible follow-up. Digital tools could support these activities as they are developed and validated.
Building a platform with room to expand
Presbyopia gives Yolia a clear initial commercial focus. Longer-term opportunities in other vision needs and formulation or lens-delivery innovations can be presented as development pathways, with their own evidence and commercialization requirements. They offer strategic options without requiring overlapping market estimates to be combined.
Yolia’s strongest market story brings three elements together: a widespread and enduring need, an established professional and manufacturing ecosystem, and a personalized nonsurgical treatment proposition. Demonstrating that proposition in a focused patient segment would create a foundation for broader clinical adoption, partnerships and geographic growth.
The opportunity is to make personalized vision care a practical service that patients value and clinicians can deliver consistently.
Sources
- Fricke TR et al. Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia: Systematic Review, Meta-analysis, and Modelling. Ophthalmology, 2018. Original study.
- World Health Organization. Ageing and health.
- Nichols JJ, Fisher D; market contribution by Jeff Johnson. Contact Lenses 2025. Contact Lens Spectrum, January–February 2026.
- Alcon. Full-year 2025 financial results, February 24, 2026.
- CooperCompanies. Fiscal 2025 Form 10-K.
- NIQ. A new era for vision correction, April 7, 2026.